Lakeshore Biopharma CO Ltd (LSB)

$3.33 -0.24 (-6.80%)
Market Cap 30.99M
Revenue (ttm) 80.82M
Net Income (ttm) -61.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.59%
Debt to Equity Ratio 0.61
Volume 27,000
Avg Vol 46,792
Day's Range N/A - N/A
Shares Out 9.31M
Stochastic %K 77%
Beta 0.81
Analysts Strong Sell
Price Target $5.25

Company Profile

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 10 8920 2086
Address:
Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, China
khixst
khixst Aug. 22 at 4:08 PM
Discovering the Next Wave of Biotech Innovation $MDCX, $RNXT, $JSPR, $LSB https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34326302/discovering-the-next-wave-of-biotech-innovation-mdcx-rnxt-jspr-lsb/
0 · Reply
TimmyTheBull
TimmyTheBull Aug. 18 at 9:42 PM
$LSB there should be a bigger BO coming
0 · Reply
LittleIronman2
LittleIronman2 Aug. 18 at 2:48 PM
$LSB what happens to the warrants
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 18 at 12:37 PM
LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside $LSB https://stocktwits.com/news/equity/markets/lakeshore-biopharma-got-an-acquisition-proposal-from-oceanpine-capital/chsO9ANRdXT
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Aug. 10 at 11:09 AM
$QNTM $IBO $ALUR $GLTO $LSB $QNTM is targeting 3 big markets: • MS repair • Hangover relief • Alcohol detox Debt-free, $10.3M in assets, funded through 2027. Which catalyst hits first — Phase 2 MS trial, Unbuzzd sales growth, or REKVRY trial results? https://analyticainvestor.beehiiv.com/p/quantum-biopharma-taking-brain-health-in-bold-new-directions-803d3cda283ced6d
0 · Reply
jniravel
jniravel Aug. 6 at 6:52 PM
$LSB where is the support zone? Down for weeks
0 · Reply
jmmoore4
jmmoore4 Aug. 1 at 7:15 PM
$LSB 🚮
0 · Reply
BigThurston
BigThurston Jul. 31 at 3:42 PM
$LSB new floor? Price target $0.80- $0.92
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 12:21 PM
✅ 💊 $LSB Entry: $0.86 → Target: $1.29
1 · Reply
LittleIronman2
LittleIronman2 Jul. 30 at 8:00 PM
$LSB what a dud
0 · Reply
Latest News on LSB
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

Aug 18, 2025, 8:00 AM EDT - 4 days ago

LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

LakeShore Biopharma Announces Fiscal Year 2025 Financial Results

Jul 31, 2025, 2:55 PM EDT - 22 days ago

LakeShore Biopharma Announces Fiscal Year 2025 Financial Results

LakeShore Biopharma Announces US$15 Million Private Placement Financing

Jul 8, 2025, 7:25 AM EDT - 6 weeks ago

LakeShore Biopharma Announces US$15 Million Private Placement Financing

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

Apr 23, 2025, 9:35 AM EDT - 4 months ago

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

Dec 19, 2024, 9:05 AM EST - 8 months ago

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

Dec 12, 2024, 7:57 PM EST - 9 months ago

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 29, 2024, 8:30 AM EDT - 10 months ago

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

Oct 25, 2024, 8:30 AM EDT - 10 months ago

LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

Oct 8, 2024, 8:30 AM EDT - 11 months ago

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

Sep 27, 2024, 7:00 AM EDT - 11 months ago

LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

LakeShore Biopharma Announces Leadership Transitions

Sep 4, 2024, 8:00 AM EDT - 1 year ago

LakeShore Biopharma Announces Leadership Transitions

LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition

Jul 5, 2024, 7:00 AM EDT - 1 year ago

LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition

YS Biopharma Announces Name Change to LakeShore Biopharma

May 24, 2024, 7:30 AM EDT - 1 year ago

YS Biopharma Announces Name Change to LakeShore Biopharma

YS Biopharma Announces Results of Extraordinary General Meeting

May 21, 2024, 4:15 PM EDT - 1 year ago

YS Biopharma Announces Results of Extraordinary General Meeting

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

May 7, 2024, 4:20 PM EDT - 1 year ago

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Apr 29, 2024, 8:00 AM EDT - 1 year ago

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript

Apr 19, 2024, 9:10 AM EDT - 1 year ago

YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

Apr 19, 2024, 7:00 AM EDT - 1 year ago

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

Apr 18, 2024, 8:00 AM EDT - 1 year ago

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

Apr 16, 2024, 8:00 AM EDT - 1 year ago

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

Apr 9, 2024, 8:00 AM EDT - 1 year ago

YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

Apr 3, 2024, 8:00 AM EDT - 1 year ago

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

Mar 5, 2024, 8:00 AM EST - 1 year ago

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

Feb 22, 2024, 5:00 PM EST - 1 year ago

YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

Feb 16, 2024, 8:20 PM EST - 1 year ago

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

Feb 16, 2024, 5:36 PM EST - 1 year ago

Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

Feb 14, 2024, 8:00 AM EST - 1 year ago

YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

YS Biopharma Announces Appointment of New Directors

Feb 14, 2024, 7:50 AM EST - 1 year ago

YS Biopharma Announces Appointment of New Directors

YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.

Feb 12, 2024, 8:50 AM EST - 1 year ago

YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.

YS Biopharma Announces US$40 Million Private Placement Financing

Feb 9, 2024, 6:30 AM EST - 1 year ago

YS Biopharma Announces US$40 Million Private Placement Financing

Shareholders of YS Biopharma Announce an Extraordinary General Meeting

Feb 8, 2024, 6:10 PM EST - 1 year ago

Shareholders of YS Biopharma Announce an Extraordinary General Meeting

YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024

Jan 22, 2024, 5:00 PM EST - 1 year ago

YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024

YS Biopharma Announces Changes to its Board Committees

Jan 8, 2024, 8:00 AM EST - 1 year ago

YS Biopharma Announces Changes to its Board Committees

YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting

Dec 20, 2023, 4:30 PM EST - 1 year ago

YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting

YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023

Dec 20, 2023, 8:56 AM EST - 1 year ago

YS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

Nov 14, 2023, 8:30 AM EST - 1 year ago

Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target

YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

Oct 31, 2023, 8:30 AM EDT - 1 year ago

YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

YS Biopharma Announces Receipt of Nasdaq Notice

Oct 26, 2023, 8:30 AM EDT - 1 year ago

YS Biopharma Announces Receipt of Nasdaq Notice

YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

Sep 26, 2023, 8:30 AM EDT - 2 years ago

YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection

Sep 15, 2023, 8:30 AM EDT - 2 years ago

YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection

YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference

Sep 5, 2023, 8:30 AM EDT - 2 years ago

YS Biopharma to Participate in Participate in Citi's 18th Annual Biopharma Conference

YS Biopharma Announces Purchase of Shares by Company Officers

Aug 24, 2023, 4:15 PM EDT - 2 years ago

YS Biopharma Announces Purchase of Shares by Company Officers

YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024

Aug 15, 2023, 5:00 PM EDT - 2 years ago

YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

Jul 26, 2023, 5:00 PM EDT - 2 years ago

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023

Jul 21, 2023, 4:30 PM EDT - 2 years ago

YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA

Jun 1, 2023, 8:30 AM EDT - 2 years ago

YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA

Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)

May 26, 2023, 8:56 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)

CHRS ICPT SRDX

YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023

May 18, 2023, 8:25 AM EDT - 2 years ago

YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023

khixst
khixst Aug. 22 at 4:08 PM
Discovering the Next Wave of Biotech Innovation $MDCX, $RNXT, $JSPR, $LSB https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34326302/discovering-the-next-wave-of-biotech-innovation-mdcx-rnxt-jspr-lsb/
0 · Reply
TimmyTheBull
TimmyTheBull Aug. 18 at 9:42 PM
$LSB there should be a bigger BO coming
0 · Reply
LittleIronman2
LittleIronman2 Aug. 18 at 2:48 PM
$LSB what happens to the warrants
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 18 at 12:37 PM
LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside $LSB https://stocktwits.com/news/equity/markets/lakeshore-biopharma-got-an-acquisition-proposal-from-oceanpine-capital/chsO9ANRdXT
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Aug. 10 at 11:09 AM
$QNTM $IBO $ALUR $GLTO $LSB $QNTM is targeting 3 big markets: • MS repair • Hangover relief • Alcohol detox Debt-free, $10.3M in assets, funded through 2027. Which catalyst hits first — Phase 2 MS trial, Unbuzzd sales growth, or REKVRY trial results? https://analyticainvestor.beehiiv.com/p/quantum-biopharma-taking-brain-health-in-bold-new-directions-803d3cda283ced6d
0 · Reply
jniravel
jniravel Aug. 6 at 6:52 PM
$LSB where is the support zone? Down for weeks
0 · Reply
jmmoore4
jmmoore4 Aug. 1 at 7:15 PM
$LSB 🚮
0 · Reply
BigThurston
BigThurston Jul. 31 at 3:42 PM
$LSB new floor? Price target $0.80- $0.92
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 12:21 PM
✅ 💊 $LSB Entry: $0.86 → Target: $1.29
1 · Reply
LittleIronman2
LittleIronman2 Jul. 30 at 8:00 PM
$LSB what a dud
0 · Reply
jmmoore4
jmmoore4 Jul. 30 at 4:37 PM
$LSB 📈
0 · Reply
BigThurston
BigThurston Jul. 30 at 3:39 PM
$LSB going places🫶
1 · Reply
jmmoore4
jmmoore4 Jul. 29 at 4:00 PM
$LSB This could really run. ⬆️
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 29 at 3:29 PM
✅ 💊 $LSB Entry: $1.13 → Target: $1.37
1 · Reply
Stocks771
Stocks771 Jul. 25 at 4:54 AM
$LSB
0 · Reply
Horizon_Trades
Horizon_Trades Jul. 24 at 5:28 PM
$LSB Currently great momentum. Holding a position at $1.01
0 · Reply
Sydney_Sweeneys_Bra
Sydney_Sweeneys_Bra Jul. 23 at 12:26 PM
$LSB flipped this for profit twice in the last four weeks. Thank you, LSB!
0 · Reply
Dusty_Bunz
Dusty_Bunz Jul. 21 at 5:54 PM
$LSB Out at break even
0 · Reply
Dusty_Bunz
Dusty_Bunz Jul. 18 at 8:21 PM
$LSB Looking to get out break even 1.14
0 · Reply
stockanalysis_
stockanalysis_ Jul. 15 at 8:17 PM
After Hours Losers: $CYCC $PCLA $SNAL $GRO $LSB View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading
0 · Reply
Gbeezy
Gbeezy Jul. 11 at 2:47 PM
$LSB the CCP thanks you for your generous donations
0 · Reply
Tenpincher
Tenpincher Jul. 10 at 3:59 PM
$LSB Needs to hold the 20 & 50 daily MA (1.06-1.07) by the close or the play is off.
0 · Reply